Withdrawn depression study sought to measure food cravings with a computer test

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Depressed patient group 1. to be between 20- and 60-year-old; 2. to meet the DSM-5 diagnostic criteria for major depressive disorder; 3. to experience moderate to severe symptoms interfering with the daily functioning, as indicated by a score above 20 on the Montgomery and Asberg depression scale (MADRS); 4. to understand and accept the experimental procedure and constraints of the present study; 5. to give written consent for the participation to the study; and, 6. to be a beneficiary of or affiliated to a health insurance plan. Healthy volunteer group 1. to be between 20- and 60-year-old; 2. to be free from any history of psychiatric disorder (substance abuse or alcohol abuse, dependence, mood disorders, etc.) that may require the prescription of long-term psychotropic treatment; 3. to understand and accept the experimental procedure and constraints of the study; 3\) to give written consent for the participation to the study; and, 4) to be a beneficiary of or affiliated to a health insurance plan Exclusion Criteria: * Depressed patient group 1. to have a previous history of somatic disease (hypertensive heart disease, Raynaud's syndrome, diabetes, adrenal insufficiency, Cushing's syndrome, peripheral neuropathy, epilepsy ...) or requiring long-term corticosteroid therapy; 2. to experience serious visual disturbances affecting the visual perception of colors; 3. to meet the DSM-5 diagnostic criteria for a primary psychiatric disorder such as bipolar disorder, schizophrenia, substance abuse / dependence or alcohol abuse, except for social phobia and generalized anxiety disorder that are commonly comorbid to major depression; 4. to exhibit a moderate or high suicidal risk, assessed by using the corresponding section of the so-called structured diagnostic psychiatric interview "Mini International Neuropsychiatric Interview" (M.I.N.I. 6.0); 5. to be exposed to the initiation of an antidepressant treatment with either a selective serotonin reuptake inhibitor or a dual serotonin-norepinephrine reuptake inhibitor within the week prior to the study or to be exposed to a change in the daily dosage of such an ongoing antidepressant treatment within the week preceding the study due to its potential sedative and orexigenic properties; 6. to be exposed to an antidepressant treatment with antagonists at the presynaptic alpha-2 norepinephrine receptors or with tricyclic agents within the week prior to the study due to their potential sedative and orexigenic properties related to their anti-H1 pharmacological profile; 7. to be exposed to the initiation of anxiolytic/hypnotic treatment within the week before the study or to be exposed to a change in the daily dosage of such an ongoing anxiolytic/hypnotic treatment within the week prior to the study due to its potential sedative properties in relation with its GABAergic activity; 8. to be exposed to an antipsychotic treatment within the week prior to the study due to its potential sedative and orexigenic properties related to its anti-H1 pharmacological profile; 9. to be exposed to alcohol consumption within 2 days before the study 10. to have a body mass index \<18.5 or ≥ 30; 11. to undergo involuntary hospitalization; 12. to be a pregnant, parturient or nursing women; 13. to be a subject deprived of its liberty by judicial or administrative decision 14. to be a subject under the safeguard measures; and, 15. to be a subject undergoing an exclusion period for another clinical research Healthy volunteer group 1. to have a previous history of somatic disorders, including neurological disease; 2. to experience serious visual disturbances affecting the visual perception of colors; 3. to be exposed to alcohol consumption within 2 days before the study 4. to have a body mass index \<18.5 or ≥ 25; 5. to undergo involuntary hospitalization; 6. to be a pregnant, parturient or nursing women; 7. to be a subject deprived of its liberty by judicial or administrative decision 8. to be a subject under the safeguard measures; and, 9. to be a subject undergoing an exclusion period for another clinical research